Ladostigil

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2005-2015
01220052015

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Present anti-PD and -AD drugs have limited symptomatic activity and devoid of neuroprotective and neurorestorative property that… (More)
  • figure 1
Is this relevant?
2013
2013
The current study determined the effects of chronic treatment of aging rats with ladostigil, a cholinesterase (ChE) and monoamine… (More)
  • figure 1
  • figure 2
  • figure 4
  • figure 3
  • figure 5
Is this relevant?
2012
2012
Impaired mitochondrial function accompanied by microglial activation and the release of nitric oxide (NO) and pro-inflammatory… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2011
2011
Oxidative stress and glial activation occur in the aging brain. Ladostigil is a new monoamine oxidase (MAO) and… (More)
Is this relevant?
2008
2008
The multifunctional, anti-Alzheimer drug, ladostigil (TV3326) [(N-propargyl-(3R) aminoindan-5yl)-ethyl methyl carbamate] combines… (More)
Is this relevant?
2008
2008
The current therapeutic advance in which future drugs are designed to possess varied pharmacological properties and act on… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2007
2007
Glial activation and oxidative-nitrative stress occur at an early stage in Alzheimer's disease (AD). In a rat model of AD… (More)
Is this relevant?
2007
2007
A 25-35% reduction of brain cytochrome oxidase (COx) activity found in Alzheimer's disease (AD) could contribute to neuronal… (More)
Is this relevant?
2006
2006
The recent therapeutic approach in which drug candidates are designed to possess diverse pharmacological properties and act on… (More)
Is this relevant?